JUN 20, 2018 06:23 AM PDT

New Drug 'Moxidectin' for River Blindness

WRITTEN BY: Nouran Amin

A new treatment to help eliminate a neglected tropical disease was developed thanks in part to an incentive program devised by researchers at Duke University.

Moxidectin, a macrocyclic lactone created by the drug company Medicines Development for Global Health, was recently approved by The U.S. Food and Drug Administration.

Moxidectin seeks to treat helminthic infections that affect more than 15 million people worldwide. The firm will be awarded a voucher for priority review of another drug, under a system first proposed by David Ridley, a professor at Duke University’s Fuqua School of Business, Henry Grabowski of the Duke Department of Economics, and Jeffrey Moe, of the Duke Global Health Institute.

“With a new treatment, we’re one step closer to eliminating river blindness,” Ridley said. “And the developer is a non-profit company,” explains David Ridley, a professor at Duke University’s Fuqua School of Business.

River blindness, or onchocerciasis, is typically found in economically-distressed areas in sub-Saharan Africa. The clinical trials published in The Lancet medical journal found that moxidectin to be more effective in treating river disease than any current treatment.

Moxidectin is a anthelmintic medicine that targets the parasite's glutamate-gated chloride ion channels. These ion channels are crucial to the function of invertebrate nerve and muscle cells. Moxidectin has activity against O. volvulus microfilariae, the parasite involved in river blindness disease, but does not have an effect on adult O. volvulus parasites.

 

Individuals with river blindness administered moxidectin had adverse events consistent with those associated with efficacy. The nature and severity of these effects from moxidectin recipients were similar to another drug known as ivermectin.

 

Eosinophilia, pruritus, musculoskeletal pain, headache, lymphopenia, tachycardia, rash, abdominal pain, hypotension, pyrexia, leukocytosis, influenza-like illness, neutropenia, cough, lymph node pain, dizziness, diarrhea, hyponatremia and peripheral swelling; were are all considered to be the most common adverse reactions.

 

However, the efficacy of repeat administrations of moxidectin have yet to be examined. Moxidectin is given as 2 mg tablets for administration as an 8 mg dose per oral to patients at least 12 years of age with O. volvulus infection.

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 23, 2018
Cannabis Sciences
NOV 23, 2018
Rimonabant: A Cautionary Tale for Targeting the Endocannabinoid System
The evidence that the endocannabinoid system (ECS) is intimately involved in food intake has been steadily increasing. Thus, in attempts to treat obesity,...
JAN 01, 2019
Drug Discovery
JAN 01, 2019
Restoring The Fountain of Youth
According to a study published in Nature Communications, a drug treatment that aided the immune system in eradicating old cells in aging mice assisted in t...
JAN 07, 2019
Cell & Molecular Biology
JAN 07, 2019
Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer
Between 12 and 17% of all breast cancer cases are triple-negative, a highly aggressive type with few therapeutic options....
JAN 17, 2019
Microbiology
JAN 17, 2019
Ulcerative Colitis Relieved by Fecal Microbiota Transplant
The community of microbes in our gut is critical to our health. If it's out of balance, researchers are investigating whether 'healthy' fecal material can restore it....
JAN 19, 2019
Drug Discovery
JAN 19, 2019
Therapeutic Avenues in Chronic Liver Disease
Known as being a silent killer, diagnosing chronic liver disease in its early stages remains a clinical challenge because of no apparent symptoms until the...
FEB 08, 2019
Drug Discovery
FEB 08, 2019
Drug Combination Generates New Neurons from Neighboring Cells
In a study published in Stem Cell Reports, scientists at Penn State University have developed a drug cocktail that converts neighboring cells—often k...
Loading Comments...